Skip to main content

Zynquista FDA Approval Status

FDA Approved: No
Brand name: Zynquista
Generic name: sotagliflozin
Company: Lexicon Pharmaceuticals, Inc.
Treatment for: Diabetes, Type 1

Zynquista (sotagliflozin) is an investigational dual SGLT1 and SGLT2 inhibitor for use in combination with insulin therapy to improve glycemic control in adults with type 1 diabetes mellitus.

Development Timeline for Zynquista

Jan 14, 2021Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure
Mar 25, 2019FDA Issues Complete Response Letter for Zynquista (sotagliflozin)
Jan 17, 2019FDA Advisory Committee Votes on Zynquista (sotagliflozin) as Treatment for Adults with Type 1 Diabetes
May 22, 2018FDA to Review Zynquista (sotagliflozin) as Potential Treatment for Type 1 Diabetes
Mar 26, 2018Lexicon Pharmaceuticals Announces Regulatory Submissions for Sotagliflozin to Treat Adults with Type 1 Diabetes

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.